Seeking Alpha
 

Enzon Pharmaceuticals, Inc. (ENZN)

- NASDAQ
  • Dec. 17, 2012, 10:33 AM
    Shares of Enzon Pharmaceuticals (ENZN) have resumed trading following an earlier halt, and the shares are currently up 5.4%. Carl Icahn has a 13.29% stake in Enzon, and disclosed in November that he and his associates wanted to discuss the operations and direction of the company.
    | Comment!
  • Dec. 17, 2012, 9:10 AM
    Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
    Losers: NBG -13%. CLWR -11%. SQNM -6%.
    | Comment!
  • Dec. 17, 2012, 7:28 AM
    Enzon Pharmaceuticals (ENZN) halts clinical development and has hired Lazard to explore a sale of the company. The move comes about 2 weeks after Carl Icahn renewed his push for a change in direction. Shares halted. (PR)
    | Comment!
  • Dec. 6, 2012, 12:45 PM
    Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
    Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%.
    | Comment!
  • Dec. 6, 2012, 9:10 AM
    Premarket gainers: WLT +7%. ZNGA +6%. AKAM +5%.
    Losers: ENZN -28%. VRA -10%. MW -10%. COST -7%. ERJ -6%. LFVN -6%. LVS -5%.
     
    | Comment!
  • Nov. 29, 2012, 5:34 PM
    Enzon Pharmaceuticals (ENZN) declares special dividend of $2.00/share. For shareholders of record Dec 10. Payable Dec 21. Ex-div date Dec 06. (PR)
    | Comment!
  • Nov. 28, 2012, 3:29 PM
    Enzon Pharmaceuticals (ENZN -0.6%) slip after activist investor Carl Icahn files an amended 13D requesting a discussion on the company's operations and direction, as well as the it's plans to preserve shareholder value.
    | Comment!
  • Feb. 28, 2012, 5:42 PM
    Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon.
    | Comment!
  • Dec. 16, 2010, 9:00 AM
    Premarket gainers: CUR +11%. CCME +9%. UEC +7%. VG +7%. ENZN +7%. NVAX +6%. ERIC +4%. ARO +4%. MORT +4%. PCBC +4%. MCP +4%.
    Losers: RGS -8%.
    | Comment!
  • Nov. 9, 2009, 8:33 AM
    Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted.
    | Comment!
  • Oct. 22, 2009, 1:56 PM
    Why aren't you blogging, Carl Icahn? "I've been sort of busy. And right now, with the market up, there's not as much interest in corporate governance like there was a couple of months ago." Damien Park notes Carl's been among the most active of activists, seeking board seats at Enzon Pharmaceuticals (ENZN), Biogen (BIIB), Amylin (AMLN) and Lions Gate (LGF), and contuining to pester Yahoo (YHOO).
    | 1 Comment
  • May 29, 2009, 8:10 AM
    Next stop Biogen: Carl Icahn's fight for seats on the board of Biogen Idec (BIIB) comes to a vote Wednesday, June 3. He owns 5.6% of the biotech group. Proxy advisory service RiskMetrics Group is backing two of Icahn's nominees. Icahn gained a seat on Amylin's (AMLN) board this week and is lobbying to ouster top management at Enzon (ENZN).
    | 1 Comment
  • May 26, 2009, 9:18 AM
    A new activist-investor attack on Enzon Pharmaceuticals (ENZN), led by Carl Icahn, is based on an obscure law that allows investors to lobby fellow shareholders for 51% of their votes in a one-time referendum to ouster top management. A win could have broad implications.
    | Comment!
Visit Seeking Alpha's
ENZN vs. ETF Alternatives
Company Description
Enzon Pharmaceuticals Inc is related to sales of drugs by various companies. It generates revenues from the sales of products namely, PegIntron, Sylatron, Macugen and CIMZIA.
Sector: Healthcare
Industry: Biotechnology
Country: United States